TFH phenotype and response to tucidinostat in relapsed/refractory PTCL: analysis of patients from a phase IIb trial.
Izutsu K, Fujimoto A, Rai S, Maruyama D, Ohmachi K, Yokohama A, Tsukasaki K, Uchida T, Kuroda J, Choi I, Hidaka M, Ando J, Sakamoto T, Kato H, Minami H, Yoshida S, Yamamoto M, Gillings M, Onogi H, Takeuchi K.
Izutsu K, et al. Among authors: fujimoto a.
Int J Hematol. 2026 Jun 9. doi: 10.1007/s12185-026-04237-8. Online ahead of print.
Int J Hematol. 2026.
PMID: 42262647